The district court granted Amgen's motion to dismiss the declaratory judgment complaint because no Article III controversy between the parties because Sandoz had not (at the time) submitted an application for the company's biosimilar version of Enbrel. In addition, the district court ruled that the declaratory judgment action was barred by the BPCIA, which required information exchange before any lawsuit may be instituted. The Federal Circuit affirmed.